ENSC Stock — Ensysce Biosciences Inc.: Cash, EV, Pipeline

What they do

Our corporate telephone number is (858) 263-4196. Our website address is www.ensysce.com. Information contained on our website, or connected thereto, does not constitute part of, and is not incorporated by reference into, this Annual Report on Form 10-K.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.33

Market cap

$6.4M

Cash

$39.4M

Enterprise value

-$33.0M

Balance sheet

Cash	$39.4M
Debt	$0.0M
Net cash	$39.4M
Enterprise value	-$33.0M
Basic shares	19.5M shares
Fully diluted shares	379.5M shares
Fully diluted market cap	$125.2M
Cash per share	$2.03
Quarterly burn	$2.0M
Cash runway	20.1 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

19.5M

Pre-funded warrants

0.0M

Options

0.1M

RSUs

0.0M

Warrants

1.6M

Converts

0.0M

Conv preferred

358.3M

ESPP reserve

—

FDSO

379.5M

Cap table as of 2026-08-05.

Price history

Loading ENSC daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

PF614

Phase 3 · Active Modality: small molecule prodrug (TAAP opioid)

Partnerships Product development and manufacturing collaboration with Galephar (milestone consideration modified Jul 1, 2026 to 2,171 Series C Preferred shares).

Indications

Chronic pain (Phase 3)

Status note Extended-release TAAP (Trypsin Activated Abuse Protection) prodrug of oxycodone; designed to resist abuse, overdose and misuse, with MPAR (Multi-Pill Abuse Resistance) technology for overdose protection to be applied to the PF614 program. Timing of the Phase 3 trial depends on raising sufficient capital.

PF614-MPAR

Phase 1 · Active Modality: drug delivery technology (TAAP + MPAR)

Indications

Chronic pain (overdose protection layer on TAAP opioids) (Phase 1)
Opioid use disorder (methadone prodrug) (Preclinical)

Status note Phase 1b clinical development. MPAR adds a layer of overdose protection to each TAAP product. TAAP and MPAR technology also being applied to a methadone prodrug for opioid use disorder. Federal MPAR grant funding ($5.3M remaining at Jun 30, 2026, expected to be utilized by May 2027).

Nafamostat

Phase 1 · Active Modality: small molecule

Target Trypsin

Indications

Chronic pain (Phase 1)

Status note Completed Phase 1 clinical development; among the lead product candidates being tested for chronic pain.

Cy Biopharma lead candidate (unnamed in filing)

Stage not disclosed · Active

Partnerships Acquired via Cy Biopharma, Inc. merger completed Aug 5, 2026 (Series C Preferred Stock consideration; concurrent $21.5M private placement with up to ~$38.6M additional milestone tranche).

Indications

Complex Regional Pain Syndrome (CRPS) Type 1 (Stage not disclosed)

Status note Cy Biopharma is a clinical-stage biotech focused on chronic pain therapies; its lead candidate for CRPS Type 1 has received FDA Orphan Drug Designation. Candidate name, modality and trial phase not disclosed in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PF614 capsule
Lead indication	Postoperative Pain, Acute
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06602271	Phase 3	Recruiting	Sponsor	ENSC	—	Postoperative Pain, Acute	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Ensysce Biosciences on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Perceptive Advisors	86,666	no change	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ENSC — Ensysce Biosciences Inc. ☆

What they do

Balance sheet

Share structure

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ENSC — Ensysce Biosciences Inc.